BDRX vs SXTC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of 2/9, indicating severe operational and financial distress. Despite a strong current and quick ratio suggesting short-term liquidity, the company is unprofitable across all margins, with deeply negative ROE and ROA. Valuation metrics are largely undefined due to lack of earnings and revenue data, while the stock has lost nearly all value over the past year. Insider sentiment is neutral-to-weak, and there is no analyst coverage or dividend support, amplifying risk.
SXTC presents a profile of a company in a catastrophic financial death spiral, despite a Piotroski F-Score of 5/9 suggesting baseline stability. The stock has collapsed from a 52-week high of $1047.00 to $2.06, representing a near-total loss of shareholder value. While the balance sheet shows low debt and high liquidity (Current Ratio 4.37), the operational reality is dire with an operating margin of -1011.69% and declining revenues. The extreme Price-to-Book ratio of 0.08 indicates the market has almost entirely discounted the company's asset value.
Compare Another Pair
Related Comparisons
BDRX vs SXTC: Head-to-Head Comparison
This page compares Biodexa Pharmaceuticals Plc (BDRX) and China SXT Pharmaceuticals, Inc. (SXTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.